跳至主要内容
临床试验/NCT00935506
NCT00935506已完成1 期

Evaluation of an Experimental EX Vivo Thrombosis Chamber Model in Healthy Male Subjects

Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2009年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
15
试验地点
1
主要终点
Evaluate ex vivo thrombosis chamber model by assessing the effect of anti-platelet agents on thrombus formation

研究概览

简要总结

Purpose of study is to evaluate a thrombosis chamber model

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy Subjects
  • BMI 18-30 kg/m²
  • Male ages 18-45

排除标准

  • Significant acute or chronic illness
  • History of abnormal bleeding or coagulation disorder, intracranial hemorrhage, or a family history of abnormal bleeding or coagulation disorder in a first degree relative under 50 years of age
  • Easy bruising
  • Smoking within 3 months prior to Day 1

研究组 & 干预措施

Clopidogrel + Aspirin

Experimental

干预措施: Clopidogrel (Drug)

Clopidogrel + Aspirin

Experimental

干预措施: Aspirin (Drug)

结局指标

主要结局

Evaluate ex vivo thrombosis chamber model by assessing the effect of anti-platelet agents on thrombus formation

时间窗: Period 2, Day 8

次要结局

  • Assess relationship between platelet aggregation and thrombus formation(Period 1 and Period 2)
  • Assess variability of thrombosis chamber measurements(Period 1 and Period 2)
  • Safety and tolerability of multiple doses clopidogrel and aspirin(From Day 1 through Study Discharge)

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Ex Vivo Human Thrombosis Chamber Study | 临床试验